معرفی
Jonathan Dranoff, MD, is a Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine and Director of the Steatotic Liver Disease Program at the VA Connecticut Healthcare System. He specializes in liver disease pathophysiology, with a focus on non-alcoholic fatty liver disease (NAFLD), drug-induced liver injury, and acetaminophen toxicity. His research explores interventions like exercise and coffee consumption to mitigate liver damage.
Education & Training:
- MD, Drexel University College of Medicine (1993)
- BA, Lehigh University (1991)
- Residency in Internal Medicine, Boston University Medical Center (1996)
- Fellowship in Gastroenterology, Yale University School of Medicine (1999)
Research Interests: Dr. Dranoff’s work spans hepatic fibrosis, portal hypertension, and the role of adenosine in liver protection. He leads studies on coffee’s chemoprotective effects and the safety of acetaminophen in cirrhosis patients. He contributed to AASLD guidelines on liver disease diagnostics and non-invasive assessment methods.
Awards & Honors:
- Fellow, American Society for Clinical Investigation (2022)
- Fellow, American Association for the Study of Liver Disease (2022)
- Fellow, American Gastroenterological Association (2022)
- Member, Alpha Omega Alpha Honor Medical Society
Professional Activities: He serves on NIH peer review panels and has authored over 90 publications. His lab investigates novel biomarkers and therapeutic strategies for liver diseases, including proteomic approaches to acute liver failure prognosis.
Labs & Teams: Leads the VA Connecticut Healthcare System’s Steatotic Liver Disease Program, collaborating with hepatologists and researchers on translational studies in NAFLD and fibrosis.